Characteristics of Real‐World Metastatic Non‐Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

BACKGROUND. Evidence from cancer clinical trials can be difficult to generalize to real‐world patient populations, but can be complemented by real‐world evidence to optimize personalization of care. Further, real‐world usage patterns of programmed cell death protein 1 (PD‐1) inhibitors following app...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Khozin, Sean, Abernethy, Amy P., Nussbaum, Nathan C., Zhi, Jizu, Curtis, Melissa D., Tucker, Melisa, Lee, Shannon E., Light, David E., Gossai, Anala, Sorg, Rachael A., Torres, Aracelis Z., Patel, Payal, Blumenthal, Gideon Michael, Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2018
Assuntos:
Lung Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5905694/
https://ncbi.nlm.nih.gov/pubmed/29317551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0353
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares